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Abstract  94 
Context: The currently applied reference ranges for thyroid function are under debate. Despite evidence 95 
that thyroid function within the reference range is related with several cardiovascular disorders, its 96 
association with the risk of stroke has not been evaluated previously. 97 
Design and Setting: We identified studies through systematic literature search and the Thyroid Studies 98 
Collaboration, a collaboration of prospective cohort studies. Studies measuring baseline thyroid-99 
stimulating hormone (TSH), free thyroxine (FT4) and stroke outcomes were included and we collected 100 
IPD from each study, including thyroid function measurements and incident all stroke (combined fatal 101 
and non-fatal) and fatal stroke. The applied reference range for TSH levels was between 0.45-4.49 102 
mIU/L.  103 
Results: We collected IPD on 43,598 adults with TSH within the reference range from 17 cohorts, with 104 
median follow-up of 11.6 years (interquartile range 5.1-13.9), including 449,908 person-years. Age- and 105 
sex-adjusted pooled HR for TSH was 0.78 (95% Confidence Interval [CI], 0.65-0.95, across the reference 106 
range of TSH) for all stroke and 0.83 (95% CI, 0.62-1.09) for fatal stroke. For the FT4 analyses, the HR 107 
was 1.08 (95% CI, 0.99-1.15, per SD increase) for all stroke and 1.10 (95% CI, 1.04-1.19) for fatal stroke. 108 
This was independent of cardiovascular risk factors including systolic blood pressure, total cholesterol, 109 
smoking and prevalent diabetes.  110 
Conclusion: Higher levels of TSH within the reference range may decrease risk of stroke, highlighting 111 
the need for further research focusing on the clinical consequences associated with differences within the 112 
reference range of thyroid function.   113 
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Introduction 114 
Subclinical hypothyroidism is associated with hypertension, hyperlipidemia, atherosclerosis and an 115 
increased risk of coronary artery disease (CAD) whereas subclinical hyperthyroidism is associated with 116 
an increased risk of atrial fibrillation and CAD (1-4). Subclinical thyroid dysfunction is defined by a 117 
thyroid-stimulating hormone (TSH) outside the reference range with a free thyroxine (FT4) within the 118 
reference range.  119 
However, the currently applied reference ranges for thyroid function are under debate (5,6) as thyroid 120 
function within these reference ranges is also associated with several adverse health outcomes (7-9). A 121 
previous systematic review found that lower TSH values and higher FT4 values within the reference 122 
range are associated with reduced bone mineral density, atrial fibrillation and an increased risk of 123 
fractures (8). Furthermore, higher levels of TSH and lower levels of FT4 within the reference range are 124 
associated with cardiovascular events and an unfavorable metabolic profile (8). On the other hand, a 125 
previous individual participant data (IPD) analysis provided no evidence for a higher risk of coronary 126 
heart disease within the reference range as currently defined (10). 127 
A considerable amount of data exist on the association of thyroid function within the reference range and 128 
cardiovascular risk factors such as atrial fibrillation, hypercholesterolemia and hypertension (8). While 129 
these risk factors related to differences within the reference range are also associated with cardiovascular 130 
disease, few data are available on clinical outcomes and no data are available on the risk of stroke, the 131 
second major vascular cause of morbidity and mortality worldwide (11). A previous study-level meta-132 
analysis on the association  of subclinical thyroid dysfunction and stroke risk included only a small 133 
number of  studies and did not include any analyses on TSH within the reference range (12). Assessing 134 
the consequences of differences within the reference range of thyroid function on clinical outcomes is 135 
important for understanding the definition of the reference range and to improve care and preventive 136 
measures. Furthermore, it can help identify clinical outcomes that need to be addressed in future 137 
randomized controlled trials assessing the benefits and risks of thyroid treatment in subclinical thyroid 138 
dysfunction (13). 139 
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Therefore we aimed to investigate the association between TSH and FT4 differences within the reference 140 
range and the risk of stroke (fatal and non-fatal) in an IPD analysis. An IPD analysis provides the 141 
opportunity to standardize definitions of thyroid function and statistical analyses, include unpublished 142 
data and pool results from several cohorts. Also, an IPD can provide the opportunity to conduct subgroup 143 
analyses due to the large number of events included.  144 
 145 
Material and methods 146 
Data Sources and Study Selection 147 
Studies were identified through the Thyroid Studies Collaboration (TSC). The TSC  is a consortium of 148 
cohorts with thyroid function measurements at baseline and prospective follow-up of cardiovascular 149 
outcomes (1,4,10,14-16). Its primary purpose is to examine the association of subclinical thyroid 150 
dysfunction and cardiovascular disease. Eligible cohorts were originally identified through systematic 151 
literature reviews (1) and this has been described in detail previously (12).  From the 19 cohorts identified 152 
by these two literature searches, 17 cohorts had information available on baseline thyroid function and 153 
follow-up stroke incidence, agreed to participate and were therefore eligible for the current study. No 154 
additional inclusion criteria were applied. None of the cohorts has previously published on the risk of 155 
stroke within the reference range of thyroid function, and 5 cohorts (17-21) previously published on the 156 
association of subclinical thyroid dysfunction and the risk of stroke (Table 1). Investigators from the 17 157 
eligible studies were invited to join the IPD analysis. The local Medical Ethics Committees of each 158 
included study approved the distinct original study protocols, and informed consent was obtained from all 159 
study participants by the original cohort studies. 160 
Data Extraction 161 
We requested individual participant characteristics related to prior cardiovascular risk factors and disease, 162 
including systolic blood pressure, serum total cholesterol, history of diabetes, smoking, previous 163 
cardiovascular disease and previous stroke. We also collected available information on demographic 164 
information (age, sex, race), anthropometric measurements (height and weight), medication use (thyroid 165 
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hormone replacement, lipid-lowering and anti-hypertensive therapy) and the outcome. Individual 166 
participant information from all cohorts were collected and analyzed in one center (Rotterdam, The 167 
Netherlands). The primary outcome measures were all stroke (combined fatal and non-fatal) and fatal 168 
stroke. Stroke was defined according to World Health Organization (WHO) criteria as a syndrome of 169 
rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms 170 
lasting 24 hours or longer or leading to death, with no apparent cause other than of vascular origin, 171 
including ischemic or hemorrhagic strokes.  172 
Thyroid Function Testing Definition 173 
We used a common definition of the reference range of thyroid function (i.e. euthyroidism) in order to 174 
increase comparability among the different studies and in concordance with previous analyses, (1,4,16) 175 
expert reviews (22,23) and several large cohorts (17,24,25). Euthyroidism was defined as TSH level 176 
between 0.45 and 4.49 mIU/L (1). Most studies used a third-generation TSH radioimmunoassay, but the 177 
Whickham Survey used a first-generation assay that reports higher measured TSH values than current 178 
assays, (26) for which we adjusted the range to 0.5-6.0 mIU/L to define euthyroidism, as previously 179 
described (1,15,27). In addition, the Whickham Survey was the only study to perform total T4 assays 180 
(27); the remainder of the cohorts performed FT4 assays.  181 
For FT4 values, we excluded studies that only measured FT4 in TSH values outside of the reference range 182 
for these analyses (17,20,21,28). In studies that measured FT4 independent of TSH values, we used all 183 
FT4 levels with individuals with TSH in the reference range, not limited by the FT4 reference range.  184 
Data synthesis and Statistical Analysis 185 
We performed a Cox proportional hazards model in each cohort separately to assess the association of 186 
TSH or FT4 continuously with all stroke and fatal stroke (IBM SPSS Statistics for Windows, Version 187 
21.0. Armonk, NY: IBM Corp). We investigated the linearity assumption using cubic restricted splines 188 
(rms package, R-project, Institute for Statistics and Mathematics, R Core Team (2013), Vienna, Austria, 189 
version 3.0.2). Due to departure from linearity for the TSH analysis in the 4D cohort (p for non-linearity = 190 
0.03), TSH was log transformed for all continuous analyses (natural logarithm). We found no departure 191 
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from non-linearity in the transformed TSH or any of the FT4 analyses and no threshold effect was 192 
therefore detected. The analyses are presented as Hazard Ratios (HR) across the reference range of TSH 193 
(0.45-4.49 mIU/L). This corresponds to the HR when comparing  participants with a TSH in the upper 194 
limit of the reference range (4.49 mIU/L) to participants with a TSH in the lower limit of the reference 195 
range (0.45 mIU/L). The FT4 analyses were performed in a standardized manner (per SD) as well as per 1 196 
ng/dL increase, for which the Whickham study (27) was excluded. We assessed the proportional hazard 197 
assumption in each cohort for each outcome, by Schoenfeld residual plots and the Schoenfeld test. All 198 
studies met the proportional hazard assumption except for the Birmingham study and PROSPER trial for 199 
the analyses with TSH, for which we performed a sensitivity analysis excluding these two cohorts. There 200 
was no interaction between FT4 and TSH levels for the all stroke events or stroke mortality analyses 201 
(p=0.099 and p = 0.28 respectively), as assessed by introducing an interaction term between FT4 (ng/dL) 202 
and TSH values. 203 
We used a random-effects model according to DerSimonian and Laird (29) to pool outcomes estimates 204 
(two-step approach). Pooled estimates were summarized in forest plots using the metafor package for R 205 
(R-project, Institute for Statistics and Mathematics, R Core Team (2013), Vienna, Austria, version 3.0.2). 206 
Heterogeneity across studies was measured using the I2 statistic and 95% confidence interval (95% CI) 207 
(30).  208 
The primary analyses were adjusted for age and sex. We also conducted multivariable analyses 209 
additionally adjusting for systolic blood pressure, smoking, total cholesterol and diabetes. These 210 
covariates were available in all cohorts except for the Birmingham cohort, where none was available (20). 211 
We conducted multiple imputation of covariates in cohorts when there was ≥ 5% of missing data for the 212 
smoking, total cholesterol, systolic blood pressure or prevalent diabetes covariates, which was the case for 213 
one study (19). We considered the age and sex adjusted analysis the primary analysis because 1) 214 
covariates used in the multivariable analyses could also be considered as mediators 2) it includes all 215 
studies, whereas the multivariable analysis does not include the Birmingham cohort. 216 
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In order to evaluate the robustness of our findings and identify possible sources of heterogeneity and 217 
populations at risk, we conducted pre-defined subgroup and sensitivity analyses. We performed stratified 218 
analyses by age, sex, history of stroke, subtype of stroke (including only classified strokes) and race, in 219 
concordance with previous reports (1,4). If the parameter estimates were infinite due to a small number of 220 
events in a stratified study-specific analysis, we used Firth's penalized maximum likelihood bias reduction 221 
method for the Cox proportional hazards model (31,32) to estimate hazard ratios (HRs) and 95% CIs. 222 
For the continuous TSH analyses, we conducted the following sensitivity analyses: 1) excluding 223 
participants who had thyroid-hormone replacement at baseline and during follow-up 2) excluding studies 224 
that included transient ischemic attack as a stroke event 3) excluding studies with self-reported stroke data 225 
4) excluding studies that did not meet the proportional hazard assumption 5) excluding cohorts with 226 
potential co-morbidities (e.g. diabetes patients) and 6) excluding studies without formal adjudication 227 
procedures. We also conducted additional multivariable analyses including prevalent atrial fibrillation, 228 
prevalent cardiovascular disease, body mass index (BMI) or lipid-lowering, and anti-hypertensive therapy 229 
at baseline to the previous multivariable model. Furthermore, we performed the following methodological 230 
sensitivity analyses: 1) perform the meta-analysis in a two-step approach using the restricted maximum-231 
likelihood estimator also using the metafor package and 2) calculate the risk estimates using a one-step 232 
frailty Cox proportional hazards model (coxme package, R-project, Institute for Statistics and 233 
Mathematics, R Core Team (2013), Vienna, Austria, version 3.0.2.) We assessed age- and sex-adjusted 234 
funnel plots and conducted Egger tests (33) to evaluate potential publication bias statistically. There was 235 
no specific funding for this study. 236 
 237 
Results 238 
We identified 17 cohorts from the United States (17,21,34), Europe (18,20,24,27,28,35-40), Australia 239 
(25), Brazil (41) and Japan (19) that assessed stroke outcomes prospectively and agreed to share IPD 240 
(Table 1). The included studies provided information on a total of 43,598 participants with thyroid 241 
function within the reference range and a follow-up from 1972 to 2014, a median follow-up ranging 242 
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between 1.5 and 20 years and a total follow-up of 450,684 person-years. All studies, except one (34), 243 
included both female (49.6%) and male participants. All cohorts reported fatal stroke and 12 studies 244 
reported both fatal and non-fatal stroke, contributing to the all stroke analyses among 34,853 participants. 245 
During follow-up, 2271 participants had a stroke, with an incidence rate of 6.3 per 1000 person-years and 246 
907 a fatal stroke with 2.0 per 1000 person-years. The FT4 analyses included 24,888 participants for all 247 
stroke and 32,580 for fatal stroke. Two studies (25,39) used variations of the WHO criteria to define all 248 
stroke and fatal stroke (Supplemental Table 1) and four studies included information on type of stroke 249 
(hemorrhagic versus ischemic) (17,21,28,40). One study (39) used questionnaires for the assessment of 250 
non-fatal stroke. Formal adjudication, defined as having clear criteria for the outcomes that were reviewed 251 
by experts for each potential case, was used for all stroke in six studies (17,21,28,36,42,43) and for fatal 252 
stroke in two additional studies (34,38). 253 
All but three cohorts had information on participants' race (18,24,25). For the additional multivariate 254 
analyses, information on AF at baseline was available for eight studies (17,18,21,25,35,36,39,40,42). 255 
Data on lipid-lowering and hypertensive medications were not available in all but two studies (19,24). 256 
Data on history of cardiovascular disease were not available for two studies (34,35). 257 
All studies provided information on the proportion of participants taking thyroid hormone medication at 258 
baseline. In all but four cohorts, none of the participants used thyroid medication at baseline. In the 259 
cohorts where thyroid medication was used, the proportion varied from 1 to 6%. All but six studies also 260 
provided follow-up information on thyroid hormone replacement use, with a range between 0 and 3%.  261 
The association between TSH and the risk of stroke 262 
The age- and sex-adjusted pooled HR for all stroke was 0.78 (95% CI, 0.65-0.95, across the reference 263 
range of TSH mIU/L) and for fatal stroke 0.83 (95% CI, 0.62-1.09) (Figure 1). This corresponds to a 264 
1.28-fold and 1.20-fold increase in all and fatal stroke risk respectively for a participant with a TSH in the 265 
lower limit of the reference range (0.45 mIU/L) compared to a participant with a TSH in the upper limit 266 
of the reference range (4.49 mIU/L).We found no heterogeneity for the analyses of all stroke or fatal 267 
stroke analyses (I2=0%). Multivariable analyses, adjusting for sex, age, smoking, total cholesterol, 268 
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systolic blood pressure and history of diabetes yielded similar results with a HR of 0.76 (95% CI, 0.63-269 
0.91) for all stroke and 0.78 (95 % CI, 0.58-1.07) for fatal stroke (Table 2). Subsequent subgroup 270 
analyses did not show a differential risk when stratifying by sex, age groups, history of stroke or race 271 
(Table 2). The information on type of stroke was available in a subgroup of 11,192 participants in four 272 
studies (17,21,28,40). Stratifying by type of stroke showed a lower estimate in hemorrhagic fatal stroke 273 
compared to ischemic stroke (HR 0.37, 95% CI 0.12-1.12 vs HR 0.78, 95% CI 0.33-1.80), but with an 274 
insignificant p for interaction (p= 0.30). Sensitivity analyses excluding specific studies or participants 275 
using thyroid hormone replacement therapy did not meaningfully affect the risk estimates (Supplemental 276 
Table 2). Additional adjustment for prevalent atrial fibrillation, prevalent cardiovascular disease (defined 277 
as previous coronary heart disease or stroke), BMI or lipid-lowering and anti-hypertensive therapy did not 278 
attenuate the associations. Estimates derived by the methodological sensitivity analyses were similar to 279 
the results of the two-step random-effects model according to DerSimonian and Laird (Supplemental 280 
Table 3). We did not find any evidence of publication bias for the TSH analyses, either with visual 281 
assessment of age- and sex-adjusted funnel plots or with the Egger test for all stroke (p = 0.75) or fatal 282 
stroke (p = 0.29).  283 
The association between FT4 and the risk of stroke 284 
The age- and sex-adjusted pooled HR for the per SD increase of FT4 and stroke analyses were 1.08 (95% 285 
CI, 0.99-1.15) for all stroke and 1.10 (95% CI, 1.04-1.19) for fatal stroke (Table 3, Figure 2). We found 286 
substantial heterogeneity for the analyses on all stroke (I2=55%) but no heterogeneity for fatal stroke 287 
(I2=0%,). When analyzing the association per 1 ng/dL FT4 increase and risk of stroke, the age- and sex-288 
adjusted pooled HRs were 1.40 (95% CI, 0.95-2.05) for all stroke and 1.44 (95% CI, 1.10-1.89) for fatal 289 
stroke (Supplemental Table 4). Multivariable analyses, adjusting for sex, age, smoking, total cholesterol, 290 
systolic blood pressure and history of diabetes did not change risk estimates substantially (Table 3).  291 
Subsequent subgroup analyses showed a differential risk for the different age categories, where the risk 292 
estimates went from protective to deleterious with increasing age (p for trend 0.024, Table 3). When 293 
stratifying by sex, history of stroke or race no differential effects were detected. Stratifying for type of 294 
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stroke also did not show differential risk (Table 3), but this was only possible in one study that was 295 
included in the FT4 analyses. We did not find any evidence of publication bias for the FT4 and stroke 296 
analyses, either with visual assessment of age- and sex-adjusted funnel plots or with the Egger test for all 297 
stroke (p = 0.41) or for fatal stroke (p = 0.28). 298 
 299 
Discussion 300 
In the current IPD analysis of 43,598 participants from 17 prospective cohort studies, higher levels of 301 
TSH within the reference range of thyroid function were significantly associated with a lower risk of 302 
stroke in age- and sex-adjusted and in multivariable analyses. The analyses concerning the association 303 
between TSH levels and fatal stroke were qualitatively similar but did not reach statistical significance. 304 
The analyses on the association between FT4 and all stroke and fatal stroke support the finding of a 305 
higher risk of stroke with differences within the reference range of thyroid function.  306 
Thyroid dysfunction is defined by the biochemical reference ranges for TSH and FT4. These reference 307 
ranges, defining the normal range, depend on the assay used, the distribution of thyroid measurements in 308 
the population, or both. A thyroid function within the “normal range” would imply that the levels of 309 
circulating thyroid hormone are not accompanied by symptoms, an increased risk of disease or adverse 310 
events. In recent years, the applied reference ranges have been debated in the context of mainly the latter 311 
two: adverse events and diseases. Higher levels of TSH within the reference range are associated with an 312 
increase in systolic and diastolic blood pressure (44,45). Moreover, increased TSH levels within the 313 
reference range are linearly associated with an unfavorable serum lipid profile (46). On the other hand, 314 
lower TSH levels within the reference range are associated with an increased risk of heart failure, 315 
coronary heart disease and atrial fibrillation in an elderly population (7). The arbitrary nature of the cut-316 
offs currently used is an important factor hampering decision making on screening and treatment of 317 
thyroid dysfunction (13). In the context of defining the reference range of thyroid function, our study 318 
provides additional evidence that lower levels of TSH and higher levels of FT4 within the reference range 319 
are associated with a negative clinical outcome, namely stroke, a major cause of morbidity and mortality. 320 
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In contrast to blood pressure or cholesterol, reference ranges for thyroid function are currently based on 321 
distribution in the population rather than risks of major diseases. It is more challenging to establish 322 
reference ranges for thyroid function based on risk of outcomes than for cardiovascular risk factors such 323 
as blood pressure and cholesterol, where the increase in risk mainly occurs for values higher than the 324 
upper limit. However, both low and high thyroid function is associated with clinical disease, also within 325 
the reference range. Furthermore, a previous study from the TSC provided no evidence for a higher risk 326 
of coronary heart disease within the normal reference range as currently defined (10). Also, thyroid 327 
function is not solely associated with cardiovascular disease but also a wide variety of clinical outcomes 328 
including fracture risk and possibly cognitive function decline (7,14). Therefore, future research should 329 
investigate if re-evaluation of the currently used reference ranges for thyroid function is meaningful, and 330 
if so, to what extent this should be done for specific populations or subgroups (e.g. elderly). 331 
Several pathways could explain the relation between thyroid function and stroke. Thyroid hormone has 332 
direct effects on the cardiovascular system and is known to decrease systemic vascular resistance (47), 333 
increase left ventricular contractile function and alter systolic and diastolic cardiac function (48). 334 
Differences in thyroid hormone function are associated with the risk of several cardiovascular risk factors 335 
including hypertension, (49) dyslipidemia (50) and atherosclerosis (51). These changes have also been 336 
reported in subjects with subclinical thyroid dysfunction (42) and some also with differences of thyroid 337 
function within the reference range (44-46). The fact that adjustment for these cardiovascular risk factors 338 
in our multivariable analyses did not substantially alter risk estimates, suggests an effect on the risk of 339 
stroke, which is independent of classical risk factors such as hypertension.  340 
Another explanation might be that the lack of effect of multivariable adjustment is due to residual 341 
confounding or unmeasured mediators. For example, in the current analysis, additional adjustment for 342 
atrial fibrillation, a plausible biological mediator for the association between thyroid function and the risk 343 
of stroke (52), did not alter risk estimates substantially. However, detecting an effect may have been 344 
hampered by the lack of information on prevalent atrial fibrillation in nine studies and insufficient 345 
 
 
15 
 
incidence information. There was no sufficient information available on anti-coagulant medication use of 346 
participants, which did not allow for further exploration of possible mediating and confounding effects. 347 
Various abnormalities in the hemostatic system have been reported in overt (53) and subclinical thyroid 348 
dysfunction (54). Hypercoagulability is seen in hyperthyroidism while hypothyroidism has been 349 
associated with mainly hypocoagulability (55,56). Alterations in coagulability and the fibrinolytic system 350 
have been linked to a higher risk of cardiovascular disease (57). Whether hemostasis is also affected 351 
within the reference range of thyroid function is not known but might be one of the pathways that play a 352 
role in the increased risk of stroke associated with differences in thyroid function within the reference 353 
range. Changes in coagulation patterns due to thyroid hormone could imply that thyroid function tending 354 
towards hyperthyroidism might increase the risk of ischemic stroke mainly. We only had a small 355 
subgroup of studies including information on type of stroke (hemorrhagic vs ischemic), limiting our 356 
analysis on type of stroke. The exact mechanism explaining the association between differences in thyroid 357 
function within the reference range and the risk of stroke therefore remains to be determined.  358 
Previous studies have reported that the association of thyroid dysfunction with the risk of cardiovascular 359 
disease is influenced by age or sex. A study on the association of thyroid disorders and stroke found a 360 
decreased risk of ischemic stroke in treated male patients with thyroid disorders, but not in females (Sex-361 
Merker et al).  A study level meta-analysis found that subclinical hypothyroidism was associated with 362 
increased risk of ischemic heart disease and cardiovascular mortality only in younger populations (Razvi 363 
et al). In line, a study in participants of 85 years in the general population, revealed no adverse effects of 364 
abnormally high levels of TSH (Gussekloo et al). In contrast, an IPD meta-analysis of 55 287 participants 365 
did not show significant trend in risk of CHD across different age groups (Rodondi et al). In our study, 366 
stratification by age, sex and race did not reveal differential risk patterns.  It should however be noted that 367 
no study to date has looked at the association of thyroid function within the reference range and stroke by 368 
age or sex and this could be one of the reasons for the discrepancies found between previous literature and 369 
our study.   370 
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The association of TSH with the risk of stroke in participants without a prior history of stroke was similar 371 
to the overall analyses, while in participants with a prior stroke, the association was not present. The total 372 
number of participants with a history of stroke was small and therefore, the power to detect a possible 373 
differential risk between participants with and without history of stroke could have been limited. The risk 374 
of all stroke associated with FT4 levels seemed to increase with older age. However, this finding was not 375 
replicated in the TSH or fatal stroke analyses.  376 
Strengths of our study include the ability to perform an IPD analysis including 43,598 participants from 377 
17 studies, based on published and unpublished data. By performing an IPD analysis we were able to 378 
standardize the definition of reference range thyroid function and covariates within our study for the 379 
analyses. There were differences between the study populations regarding age and sex distribution, 380 
amongst others. Nevertheless, there was limited to no heterogeneity of the outcome estimates between the 381 
studies. This could indicate the robustness of the findings.  382 
Despite the large number of participants, we had limited numbers of events in those with a history of 383 
stroke and only four studies included data on type of stroke. Information needed for certain stratification 384 
and sensitivity analyses e.g. by race or prevalent atrial fibrillation was not available for some cohorts. 385 
Also, there was no information available on anti-coagulant use or anticoagulant factor levels, hampering 386 
analyses concerning possible underlying pathways. Furthermore, TSH and FT4 measurements were 387 
performed only at baseline and data on thyroid medication use during follow-up were not complete, 388 
which could change risk over time, in almost all cohorts and therefore it was not possible to take changes 389 
of thyroid function over time into account. Residual confounding cannot be excluded, as is the case in all 390 
observational studies. 391 
Conclusions 392 
In summary, higher TSH levels within the reference range were associated with a lower risk of all stroke. 393 
The analyses for fatal stroke and FT4 were qualitatively similar. These data provide additional evidence 394 
that differences within the reference range of thyroid function, as currently defined, are associated with an 395 
increased risk of a major adverse event. Future studies should investigate if re-evaluation of the currently 396 
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used reference ranges for thyroid function, which are based on fixed biochemical parameters instead of 397 
health and treatment outcomes and risk of disease and mortality, should be considered. This is pivotal 398 
information when designing randomized controlled trials sufficiently equipped to address possible risks 399 
and benefits of thyroid function treatment. 400 
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Legend of Figures 621 
Figure 1.  The association between TSH and Risk of All Stroke and Fatal Stroke* 622 
 623 
* Hazard ratios (HRs) and their 95% confidence intervals (CIs) are represented by 624 
squares and are across the range of TSH (0.45 and 4.49 mIU/L). Sizes of data markers are 625 
proportional to the inverse of the variance of the hazard ratios.  626 
Data for all stroke were available in 12 studies. Three hundred ninety-three participants 627 
were excluded from the analysis of all stroke due to missing follow-up data. Data for fatal 628 
stroke were available in 17 studies. Two hundred sixty-five participants were excluded 629 
from the analysis of fatal stroke, due to missing cause of death.  630 
Abbreviations: TSH = thyroid-stimulating hormone. 631 
 632 
 633 
Figure 2.  The association between standardized FT4 and Risk of All Stroke and Fatal Stroke* 634 
 635 
* Hazard ratios (HRs) and their 95% confidence intervals (CIs) are represented by 636 
squares and are per one increase of one standard deviation of FT4. Sizes of data markers 637 
are proportional to the inverse of the variance of the hazard ratios.  638 
Data for all stroke were available in 9 studies. Three hundred eighty-seven participants 639 
were excluded from the analysis of all stroke due to missing follow-up data. Data for fatal 640 
stroke were available in 13 studies. Twenty-seven participants were excluded from the 641 
analysis of fatal stroke, due to missing cause of death.  642 
Abbreviations: FT4 = free thyroxine643 
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Table 1. Baseline Characteristics of Individuals in the Included Studies (n = 43,598) 
Study, Year 
(Reference) 
Description of 
Study Sample 
No. Median Age 
(Range), 
years* 
Women No. 
(%) 
Thyroid 
Medication 
No. (%) at 
baseline† 
Thyroid 
Medication 
No. (%) 
follow up‡ 
TSH, Median 
(IQR) 
FT4 Mean 
(SD) § 
Follow-up 
median (IQR) 
Person 
years 
4D Study, 
1998, (18) 
Trial of 
atorvastatin in type 
2 diabetes and 
hemodialysis 
patients, Germany 
 
841 66 (30-83) 368 (43.8) 0 11 (1.3) 1.10 (0.77-1.60) 
13.90 pmol/L 
(2.92) 
1.5 (0.2-3.6) 1666 
Birmingham 
Study, 1988, 
(20) 
CDA's aged ≥ 60 y 
from primary care 
practice in 
Birmingham, 
England 
 
1015 69 (60-94) 550 (54.2) 0 NA 1.60 (1.10-1.20) NA 10.2 (5.7-10.6) 8301 
Brazilian 
Thyroid 
Study, 1999, 
(41) 
Adults from 
Japanese descent 
living in São Paulo, 
Brazil 
 
890 56 (30-92) 459 (51.6) 0 NA 1.40 (0.90-2.20) 
1.07 ng/dL 
(0.18) 
7.3 (7.1-7.5) 6274 
Busselton 
Health Study, 
1981, (25) 
Adults in 
Busselton, Western 
Australia 
 
1902 50 (18-90) 912 (47.9) 0 11 (0.6) 1.42 (1.00-1.96) 
16.35 pmol/L 
(2.89) 
20.0 (19.9-20.0) 33,825 
Cardiovascular 
Health Study, 
1989, (17) 
CDA’s with 
Medicare eligibility 
in 4 US 
communities 
 
2526 71 (64-100) 1488 (58.9) 0 52 (2.1) 2.05 (1.45-2.89) NA 14.1 (8.6-16.4) 31,099 
EPIC-Norfolk 
Study, 1995, 
(24) 
Adults living in 
Norfolk, England 
 
11,986 58 (40-78) 6365 (53.1) 0 NA 1.70 (1.20-2.30) 
12.58 pmol/L 
(3.17) 
13.4 (12.6-14.3) 153,766 
Health ABC 
Study, 1997, 
(21) 
CDA’s with 
Medicare eligibility 
in 2 US 
communities 
2170 74 (69-81) 1033 (47.6) 0 37 (1.7) 2.00 (1.37-2.72) NA 11.8 (7.5-12.2) 21,057 
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Table 1. Baseline Characteristics of Individuals in the Included Studies (n = 43,598) (continued) 
Study, Year 
(Reference) 
Description of 
Study Sample 
No. Median Age 
(Range), 
years* 
Women No. 
(%) 
Thyroid 
Medication 
No. (%) at 
baseline† 
Thyroid 
Medication 
No. (%) 
follow up‡ 
TSH, Median 
(IQR) 
FT4 Mean 
(SD) § 
Follow-up 
median (IQR) 
Person 
years 
InCHIANTI 
Study, 1998, 
(35) 
Adults aged 20-102 
years living in 
Chianti geographic 
area, Italy 
 
1049 71 (21-102) 575 (54.8) 11 (1.0) NA 1.38 (0.96-1.98) 
1.42 ng/dL 
(0.29) 
9.1 (8.2-9.2) 8435 
Leiden 85-plus 
Study, 1997, 
(36) 
Adults aged 85 
years living in 
Leiden, The 
Netherlands 
 
452 85 (NA) 290 (60.4) 0 6 (1.3) 1.65 (1.15-2.31) 
14.5 pmol/L 
(2.26) 
5.2 (2.5-8.5) 2555 
MrOS Study, 
2000, (34) 
Community-
dwelling U.S. men 
aged 65 years and 
older 
 
1410 73 (65-99) 0 83 (5.9) NA 1.97 (1.36-2.72) 
0.99 ng/dL 
(0.15) 
12.0 (8.5-12.7) 14,541 
Nagasaki 
Adult Health 
Study, 1984, 
(19) 
Atomic bomb 
survivors in 
Nagasaki, Japan 
 
2342 57 (38-92) 1419 (60.6) 27 (1.2) NA 2.60 (2.00-3.40) 
1.45 ng/dL 
(0.46) 
13.0 (12.3-13.7) 28,574 
Pisa cohort, 
2000, (38) 
Patients admitted 
to cardiology 
department in Pisa, 
Italy II 
 
2695 63 (19-92) 840 (31.2) 0 0 1.53 (1.02-2.30) 
1.19 ng/dL 
(0.24) 
2.6 (1.6-3.8) 7326 
PREVEND 
Study, 1997, 
(37) 
Adults living in 
Groningen, The 
Netherlands 
 
2493 46 (28-75) 1255 (50.3) 0 4 (0.2) 1.37 (0.99-1.90) 
12.81 pmol/L 
(2.25) 
10.9 (10.6 - 11.1) 24,621 
PROSPER 
trial, 1997, 
(28) 
Trial on the 
benefits of 
pravastatin vs 
placebo in adults 
 
 
4953 75 (69-83) 2403 (48.5) 0 28 (0.6) 1.80 (1.26-2.51) NA 3.3 (3.0 - 3.5) 15,937 
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Table 1. Baseline Characteristics of Individuals in the Included Studies (n = 43,598) (continued) 
Study, Year 
(Reference) 
Description of 
Study Sample 
No. Median Age 
(Range), 
years* 
Women No. 
(%) 
Thyroid 
Medication 
No. (%) at 
baseline† 
Thyroid 
Medication 
No. (%) 
follow up‡ 
TSH, Median 
(IQR) 
FT4 Mean 
(SD) § 
Follow-up 
median (IQR) 
Person 
years 
Rotterdam 
Study, 1989 
(40) 
Adults ≥55 years 
living in 
Rotterdam, The 
Netherlands 
 
1577 68 (55-93) 934 (59.2) 0 NA 1.54 (1.06-2.26) 
16.29 pmol/L 
(2.93) 
17.0 (11.2 - 18.9) 23,217 
SHIP Study, 
1997 (39) 
Adults in West 
Pomerania, North-
East of Germany 
 
2977 47 (20-81) 1476 (49.6) 0 90 (3.0) 0.79 (0.61-1.07) 
12.67 pmol/L 
(3.42) 
11.3 (10.6 - 11.8) 32,238 
Whickham 
Survey **, 
1974 (27) 
Adults living in 
and near Newcastle 
upon Tyne, 
England 
 
2320 46 (18-92) 1213 (52.3) 92 (4.0) 54 (2.3) 2.10 (1.20-3.00) 
8.41 pmol/L 
(1.95) 
19.0 (15.8-20.0) 37,252 
Overall 
 
43,598 64.9 (18-102) 21,580 (49.6) 213 (0.5) 293 (1.4) 1.65 (1.10-2.40) 
13.6 pmol/L 
(2.6) 
11.6 (5.1-13.9) 450,684 
Abbreviations: CDA = community-dwelling adult; IQR = interquartile range (25th-75th percentile); NA = not applicable; FT4 = free thyroxine; TSH = thyroid-stimulating hormone. 
* Participants younger than 18 years of age were not included 
† Participants with missing information on thyroid medication at baseline: Health ABC Study 7, MrOs Study 59, Rotterdam Study 463, Whickham Survey 3 
‡ Participants with missing information on thyroid medication at follow-up: Whickham Survey 1430 
§ 1 pmol/L is 0.0777 ng/dL  
II Excluded patients with acute coronary syndrome or severe illness 
**The Whickham Survey used a first-generation assay for the measurement of TSH and did not measure FT4 but total T4. 
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Table 2. Stratified Analyses for the Associations between TSH and the Risk of All Stroke and Fatal Stroke 
  
All Stroke*   Fatal Stroke† 
  
No. events/ Total 
participants 
Age and sex adjusted 
HR (95% CI) 
Multivariable‡ 
HR (95% CI) I2 
No. events/ Total 
participants 
Age and sex adjusted 
HR (95% CI) 
Multivariable‡ 
HR (95% CI) I2 
Total 
Population 
TSH 
 
2271/34,853 0.78 (0.65, 0.95) 0.76 (0.63, 0.91) 0% 907/43,333 0.83 (0.62, 1.09) 0.78 (0.58, 1.07) 0% 
Sex§ Men 1091/16723 0.80 (0.62, 1.07) 0.78 (0.60, 1.02) 0% 422/21874 0.85 (0.50, 1.41) 0.85 (0.50, 1.35) 0% 
 Women 1180/18130 0.78 (0.58, 1.07) 0.75 (0.55, 1.02) 25% 485/21459 0.80 (0.52, 1.25) 0.80 (0.52, 1.22) 12% 
 
p for interaction 
 
0.90 0.85  
 
0.86 0.85  
Age II 18. – 49 60/8305 0.95 (0.31, 2.86) 1.45 (0.37, 4.17) 0% 12/9,525 0.71 (0.07, 7.47) 1.14 (0.06, 23.85) 0% 
 
50 – 64 358/9145 0.75 (0.47, 1.19) 0.75 (0.47, 1.22) 0% 104/12,303 1.35 (0.55, 3.25) 1.22 (0.48, 3.16) 0% 
 
65 -79 1588/15,667 0.83 (0.67, 1.05) 0.80 (0.63, 1.00) 0% 623/19,198 0.89 (0.62, 1.27) 0.95 (0.85, 1.09) 0% 
 
≥80 265/1736 0.69 (0.40, 1.17) 0.63 (0.36, 1.09) 0% 168/2,307 0.43 (0.22, 0.85) 0.36 (0.17, 0.78) 0% 
 
p for trend 
 
0.66 0.28  
 
0.61 0.43  
Stroke 
history¶ No 1875/31,626 0.78 (0.63, 0.98) 0.75 (0.60, 0.93) 0% 710/36,222 0.71 (0.47, 1.07) 0.71 (0.47, 1.05) 24% 
 Yes 206/1266 1.00 (0.53, 1.83) 1.14 (0.60, 2.20) 0% 92/1440 0.83 (0.26, 2.50) 1.58 (0.47, 5.27) 20% 
 p for interaction  0.47 0.23   0.80 0.22  
Stroke type** Hemorrhagic 129/11,192 0.47 (0.26, 0.83) 0.47 (0.25, 0.89) 5% 87/11,192 0.38 (0.14, 1.07) 0.37 (0.12, 1.12) 27% 
 Ischemic 817/11,192 0.71 (0.50, 1.00) 0.69 (0.48,0.98) 0% 182/11,192 0.69 (0.34, 1.35) 0.78 (0.33-1.80) 0% 
 p for interaction  0.24 0.30   0.34 0.30  
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Race‡‡ White 1430/19,037 0.76 (0.60, 0.95) 0.73 (0.58, 0.91) 0% 520/23,213 0.71 (0.48, 1.02) 0.67 (0.47 1.00) 0% 
 Asian NA NA NA  63/3230 0.48 (0.06, 11.22) 0.62 (0.10, 3.97) 41% 
 Black 150/1090 0.85 (0.26, 2.78) 0.91 (0.41, 1.99) 47% 59/1055 0.95 (0.30, 3.12) 0.89 (0.26, 2.91) 0% 
  p for interaction  0.88 0.60   0.83 0.91  
Abbreviations: CI, confidence interval; HR, hazard ratio; TSH, thyroid-stimulating hormone. The HR’s are across the reference range of TSH mIU/L (0.45-4.49) 
*Data were available from 12 studies, 393 participants were excluded due to missing stroke event data. 
† 265 participants were excluded due to missing data on cause of death.  
‡ Adjusted for sex, age, systolic blood pressure, total cholesterol, smoking and prevalent diabetes at baseline. The Birmingham Study was excluded in this analysis because of lack of data on 
cardiovascular risk factors. 
§ These analyses were not adjusted for sex. 
II These HRs were adjusted for sex and age as continuous variable to avoid residual confounding within age strata. 
¶ Information on history of stroke was not available for the Pisa cohort, Birmingham Study and Busselton Health Study. Data concerning history of stroke were missing for 64 participants 
in total. 
** Information on type of stroke was available for the Cardiovascular Health Study, Health ABC Study, PROSPER and the Rotterdam Study.  
‡‡Information on race was not available for the 4D study, Birmingham study. Busselton Health Study and EPIC-Norfolk Study. Excluded 96 participants from MrOs Study due to no events 
in subgroup. 
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 Table 3. Stratified Analyses for the Associations between standardized FT4 and the Risk of All Stroke and Fatal Stroke*  
  
All Stroke†  Fatal Stroke‡  
  
No. events/ 
Total 
participants 
Age and Sex adjusted 
HR (95% CI) 
Multivariable § 
HR (95% CI) I2 
No. events/ 
Total 
participants 
Age and Sex adjusted 
HR (95% CI) 
Multivariable § 
HR (95% CI) I2 
Total Population 
FT4 per SD 
 
1307/24,888 1.08 (0.99, 1.17) 1.06 (0.99, 1.15) 55% 598/32,580 1.10 (1.04, 1,19) 1.09 (1.02, 1.18) 0% 
Sex II Men 639/11,848 1.02 (0.94, 1.11) 1.00 (0.92, 1.08) 0% 284/16,651 1.10 (0.99, 1.24) 1.08 (0.96, 1.21) 0% 
 Women 668/13,040 1.10 (0.99, 1.22) 1.10 (1.01, 1.20) 52% 314/15,929 1.12 (1.03, 1.23) 1.12 (1.01, 1.24) 0% 
 
p for interaction  0.27 0.12   0.79 0.65  
Age¶ 18 – 49y 59/8289 0.81 (0.61, 1.07) 0.75 (0.55, 1.03) 0% 12/9507 1.50 (0.62, 3.67) 0.93 (0.32, 2.71) 36% 
 
50 – 64y 342/9019 1.03 (0.93, 1.29) 1.03 (0.84, 1.27) 66% 99/11,929 1.09 (0.88, 1.35) 1.06 (0.84, 1.32) 0% 
 
65 -79y 759/6803 1.12 (1.05, 1.19) 1.10 (1.04, 1.17) 0% 376/9897  1.11 (1.01, 1.22) 1.09 (0.99, 1.21) 0% 
 
≥80 147/777 1.15 (0.98, 1.35) 1.15 (0.96, 1.38) 0% 111/1247 1.12 (0.94, 1.33) 1.09 (0.89, 1.33) 0% 
 
p for trend  0.024 0.015   0.54 0.76  
Stroke history** No 1013/22,446 1.06 (0.95, 1.18) 1.05 (0.95, 1.15) 58% 472/27,256 1.10 (1.02, 1.19) 1.09 (1.00, 1.18) 0% 
 Yes 104/483 1.11 (0.95, 1.29) 1.12 (0.95, 1.32) 0% 60/668 1.07 (0.78, 1.45) 1.15 (0.77, 1.73) 26% 
 p for interaction  0.64 0.51   0.87 0.80  
Stroke type‡‡ Hemorrhagic 17/1577 1.37 (0.82-2.29) 1.15 (0.64-2.07) NA 10/1577 1.15 (0.63-2.12) 1.01 (0.49, 2.07) NA 
 Ischemic 157/1577 1.30 (1.14-1.47) 1.20 (1.06-1.37) NA 39/1577 1.00 (0.71-1.41) 0.90 (0.62-1.28) NA 
 p for interaction  0.84 0.88 
 
 0.70 0.77 
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Race§§ White 617/10,208 1.12 (0.99, 1.26) 1.11 (0.99 1.23) 51% 319/14,528 1.13 (1.03, 1.23) 1.10 (1.00 1.21) 0% 
 Asian NA NA NA NA 63/3228 1.27 (0.74, 2.18) 1.27 (0.74, 2.18) 58% 
 Black NA NA NA NA 2/48 0.94 (0.23, 3.88) 1.00 (0.14, 7.09) NA 
  p for interaction  NA NA   0.89 0.87  
Abbreviations: CI, confidence interval; HR, hazard ratio; FT4, free thyroxine. NA, not applicable. The HRs are per one increase in standard deviation of FT4. 
*The Whickham Survey did not measure FT4 but total T4. 
† Data were available from 12 studies, 384 participants were excluded due to missing stroke event data. 
‡27 participants were excluded due to missing data on cause of death.  
§ Adjusted for sex, age, systolic blood pressure, total cholesterol, smoking and prevalent diabetes at baseline.  
II These analyses were not adjusted for sex. 
¶ These HRs were adjusted for sex and age as continuous variable to avoid residual confounding within age strata. 
** Information on stroke history was not available for the Pisa cohort, Birmingham Study and Busselton Health Study. Data on stroke history were missing for 64 subjects.  
‡‡ Information on type of stroke was available for the Rotterdam Study. 
§§Information on race was not available for the 4D study, Busselton Health Study and EPIC-Norfolk Study. Excluded 96 participants from MrOs Study due to no events in subgroup. 
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Example of electronic search strategy:  
Medline (OvidSP): 
("Thyroid Diseases"/ OR hyperthyroidism/ OR hypothyroidism/ OR "thyrotropin/bl"/ OR "thyroid function tests"/ 
OR (((thyroid*) ADJ3 (disease* OR abnormal* OR anomal* OR disorder* OR dysfunction* OR insufficien* OR 
failure* OR hyperfunction* OR subclinic* OR function*)) OR hypothyr* OR hyperthyr* OR dysthyr* OR 
((thyrotropin) ADJ3 (blood OR level* OR serum)) OR ft4).ab,ti.) AND (mortality/ OR mortality.xs. OR "Cause of 
Death"/ OR "Survival Rate"/ OR survival/ OR exp "stroke"/ OR "Ischemic Attack, Transient"/ OR "Cerebrovascular 
Disorders"/ OR "brain ischemia"/ OR (mortalit* OR "death rate" OR surviv* OR ((cerebrovascular OR "cerebro 
vascular" OR "cerebral vascular") ADJ (accident OR disease*)) OR cva OR stroke  OR "transient ischemic attack" 
OR "transient brain ischemia"  OR "transient cerebral ischemia" OR "transient ischaemic attack" OR "transient brain 
ischaemia"  OR "transient cerebral ischaemia" OR tia).ab,ti.) AND (exp "cohort studies"/ OR "controlled clinical 
trial".pt. OR "epidemiologic methods"/ OR "follow up"/ OR (cohort*).ab,ti.) 
 
  
Appendix Table 1 Additional Participant and Cohort Information   
Study name & Reference 
TSH assay, generation*,  
years performed 
Euthyroidism, range of 
TSH definition 
N excluded due 
to TSH outside 
range 
N included in 
FT4 analyses 
N with data missing 
on any covariate† 
Stroke Definition 
Formal 
Adjudication‡ 
4D Study (18) 
Immulite 2000; Siemens, 
Germany, third generation, 1998 
0·45 - 4·5 ImU/L 309 797 0 
Stroke was defined as  neurologic deficit lasting 
>24 hours. Cerebral CT or MRI available in all 
except 16 cases 
Yes 
Birmingham Study (20)  
Serono MAIA-clone method, 
second generation,1988 
0·45 - 4·5 ImU/L 176 NA NA Cerebrovascular diseases (ICD9 430-438) No 
Brazilian Thyroid Study  
(41) 
Immunofluorometric assay 
(Wallac–Delfia, PerkinElmer), 
third generation, 1999-2000 
0·45 - 4·5 ImU/L 220 890 6 
Recoded according to cause of death (ICD-9 
codes 430–438) 
No 
 
 
Busselton Health Study 
(25) 
Immulite 2000 
chemiluminescent analyzer, third 
generation, 1981 
 
0·45 - 4·5 ImU/L 202 1,900 24 
First stroke event and death from stroke ICD-9 
codes 430–438 (& ICD 10 I60-I69 including 
G45) 
No 
 
 
Cardiovascular Health 
Study (17) 
LumaTaghTSH 
chemiluminescence (Nichols 
Institute, San Juan Capistrano, 
USA), third generation, 1991-
1993 
 
0·45 - 4·5 ImU/L 587 NA 6 
First stroke event (hospitalized) and death from 
stroke for those with no history of stroke. 
Yes  
EPIC-Norfolk Study (24) (  
AutoDelfia fluoroimmunoassay 
kits (Wallac, Finland), third 
generation, 1995-1998 
0·45 - 4·5 ImU/L 1407 11,986 192 
Cerebrovascular diseases (430-438, I60-I69) on 
hospital discharge, or as underlying cause of 
death, excl. TIA 
No  
Health, Aging, and Body 
Composition Study (21)  
ACS immunoassay (Chiron Diag 
Corp, Emeryville, USA), third 
generation, 1997 
0·45 - 4·5 ImU/L 628 NA 13 
First stroke event and death from stroke 
according to adjudication 
Yes  
InCHIANTI Study (35) 
Chemiluminescent immunoassay 
(Vitros Reagent, Ortho-Clinical 
Diagnostics, Johnson & Johnson, 
Italy), third generation, 1998 
 
0·45 - 4·5 ImU/L 164 1048 26 
Recoded according to cause of death (ICD-9 
codes 430–438), local ascertainment for stroke 
events 
No  
Leiden 85-plus Study (36)  
Elecsys 2010 system + 
electrochemiluminescence 
(Boehringer, Germany), third 
generation, 1997-1999 
0·45 - 4·5 ImU/L 106 448 10 
Adjudicated first stroke event and/or death 
(ICD-10 I60-I69) 
Yes  
MrOS Study (34) 
Siemens Diagnostics, (Deerfield, 
IL, USA), third generation, 
2000-2002 
0·45 - 4·5 ImU/L 192 1410 113 
Death certificates used from start of study. 
Adjudicated death from stroke according to 
ICD9 codes 430-438 from the years 2003-2005 
onward. 
Yes  
Nagasaki Adult Health 
Study (19) 
Eiken radioimmunoassay (Eiken 
Chemical Co. Ltd., Tokyo, 
Japan), first generation, 1984-
1987 
 
0·45 - 4·5 ImU/L 488 2340 158 Stroke specific mortality (ICD-9 430-438) No  
Appendix Table 1 Additional Participant and Cohort Information (continued)  
Study name & Reference 
TSH assay, generation*, years 
performed 
Euthyroidism, range of 
TSH definition 
N excluded due 
to TSH outside 
range 
N included in 
FT4 analyses 
N with data missing 
on any covariate† 
Stroke Definition 
Formal 
Adjudication‡ 
 
 
 
Pisa cohort (38) 
AIA 600 system 
(Tosho Corp, Tokyo, Japan), 
third generation, 2000 
0·45 - 4·5 ImU/L 446 2695 175 Recoded according to cause of death No  
PREVEND Study (37) 
Microparticle enzyme 
immunoassay (Architect, Abbott 
Laboratories, Abbott Park, IL, 
USA), third generation 
0·45 - 4·5 ImU/L 210 2493 50 
Stroke event and/or death (ICD-10 I60-I69), 
excl. TIA  
No  
PROSPER Trial (28) 
electrochemiluminescenceRoche 
Elecsys 2010 (Burgess Hill, 
UK), third generation, 1997-
1999 
0·45 - 4·5 ImU/L 843 NA 0 
Adjudicated first stroke event and death from 
stroke 
Yes  
Rotterdam Study (40) 
TSH Lumitest (Henning, Berlin, 
Germany), third generation, 
1990-1992 
0·45 - 4·5 ImU/L 278 1328 3 
Adjudicated first stroke event and death from 
stroke (ICD-10 I60-I69) 
Yes  
SHIP Study (39) 
LIA-mat, Byk Sangtec 
Diagnostica 
immunochemiluminescent 
procedures (Frankfurt, 
Germany), third generation, 
1997-2001 
0·45 - 4·5 ImU/L 1269 2973 12 Self-reported stroke by questionnaire Yes  
Whickham Survey (27)  
TSH first generation assay, 
1972-1974 
0·50- 6·0 I mU/L 417 2299 36 
Stroke specific mortality and incident events 
(ICD-9 430-438) 
No  
Abbreviations: ICD international classification of disease, TIA transient ischemic attack; TSH, Thyroid-Stimulating-Hormone,CT computed tomography, MRI magnetic 
resonance imaging; N number participants; NA not applicable.  
*Third generation TSH assays have a functional sensitivity of  0·01-0·02mIU/l (the lowest TSH level at which interassay coefficient of variation is <20%) 
† Covariates are sex, age, systolic blood pressure, cholesterol, smoking and prevalent diabetes at baseline. 
‡ Formal adjudication is defined as having clear criteria for the outcomes that were reviewed by experts for each potential case 
 
 
 
 
  
Appendix Table 2. Sensitivity Analyses for the association between TSH and the Risk of All Stroke Events and Fatal Stroke* 
 
All Stroke† Fatal Stroke 
 
No. Events/Participants HR (95% CI) I2,% No. Events/Participants HR (95% CI) I2,% 
       
Primary analysis with DL estimator 2271/34,853 0·78 (0·65, 0·95) 0% 907/43,333 0·78 (0·62, 1·09) 0% 
Excluding those with thyroid medication use at 
baseline 
2263/34,750 0·78 (0·65, 0·95) 0% 902/43,120 0·80 (0·60, 1·09) 0% 
Excluding thyroid medication use at baseline and 
follow up 
1477/19,965 0·80 (0·65, 1·02) 0% 562/24,987 0·71 (0·48, 1·02) 0% 
Only studies with formal adjudication procedures‡ 1279/12,439 0·71 (0·55, 0·91) 0% 452/16,339 0·69 (0·45, 1·07) 10% 
       
Additional multivariate analyses§ 
 
     
Multivariate + prevalent AF 1383/13,369 0·75 (0·58, 0·95) 0% 481/13,233 0·71 (0·47, 1·07) 0% 
Multivariate + BMI 2271/34,853 0·76 (0·63, 0·91) 0% 868/42,320 0·80 (0·60, 1·12) 7% 
Multivariate + lipid lowering and antihypertensive 
medication 
1832/22,867 0·75 (0·60, 0·91) 0% 712/30,334 0·69 (0·50, 0·98) 0% 
Multivariate + prevalent CVD 2203/33,890 0·75 (0·62, 0·91) 0% 816/39,861 0·80 (0·56, 1·09) 5% 
  
Appendix Table 2. Sensitivity Analyses for the association between TSH and the Risk of All Stroke and Fatal Strokea (Continued) 
 All Stroke† Fatal Stroke 
 No. Events/Participants HR (95% CI) I2,% No. Events/Participants HR (95% CI) I2,% 
Studies excluded       
Atomic Bomb Survivors; Nagasaki NA NA NA 851/40,991 0·80 (0·60, 1·09) 5% 
Studies where PH assumption was not met; 
PROPSPER trial and Birmingham Study 
2037/29,900 0·80 (0·67, 0·98) 0% 838/ 37,367 0·89 (0·65, 1·19) 0% 
Stroke assessed by questionnaire; SHIP Study 2204/31,876 0·80 (0·67, 0·95) 0% 876/ 40,373 0·83 (0·60, 1·12) 5% 
Studies including TIAs as stroke events; Busselton 
Health Study 
2085/32,954 0·80 (0·65, 0·95) 0% 864/41,434 0·80 (0·60, 1·09) 2% 
Studies without community dwelling adults; 4D study, 
Pisa cohort, Prosper trial 
1971/29059 0·80(0·67, 1·00) 0% 827/34,844 0·87 (0·62,1·19 ) 0% 
Abbreviations: AF, atrial fibrillation; BMI Body-Mass Index;  CVD cardiovascular disease; HR, hazard ratio; CI, Confidence Interval;T4, free thyroxine; NA, not applicable; TIA, 
transient ischemic attack; TSH, thyroid-stimulating hormone. The HR’s are across the reference range of TSH (0·45-4·49  mIU/L) 
* The HRs were adjusted for age and sex. 
† Data were available from 12 studies. 
‡ Formal adjudication procedure is defined as having clear criteria for the outcomes that were reviewed by experts for each potential case. This was the case for the stroke events 
analysis in Cardiovascular Health Study, Health ABC Study, Leiden 85-plus Study, Rotterdam Study, 4D Study and Prosper Trial and for the fatal stroke analysis additional in MrOs 
Study and Pisa Cohort. For CHS, 44 participants were excluded because of adjudication of  stroke events was missing. 
§ The Birmingham Study was excluded from the multivariable analyses because of lack of data on cardiovascular risk factors. Multivariate analyses included adjustments for sex, age, 
systolic blood pressure, smoking and prevalent diabetes at baseline. Information on AF at baseline was available for the 4D Study, Busselton Health Study, Cardiovascular Health 
Study, Health ABC Study, InCHIANTI Study, Leiden 85-plus Study, Rotterdam Study and the SHIP study. Data on lipid-lowering and hypertensive medications were not available 
for EPIC-Norfolk and the Nagasaki Adult Health Study. Data on history of cardiovascular disease were not available for the InChianti Study and MrOs Study.  Body Mass Index 
defined as weight (kg) divided by height (m) squared. 
 
 
Appendix Table 3. Methodological Sensitivity Analyses for the Associations between TSH and the Risk of All Stroke and Fatal Stroke   
  
All Stroke*  Fatal Stroke†  
  
No. events/ Total 
participants 
Two-step DL 
HR (95% CI) 
Two-step REML 
HR (95% CI) 
One-step Cox 
HR (95% CI) 
No. events/ Total 
participants 
Two-step DL 
HR (95% CI) 
Two-step REML 
HR (95% CI) 
One-step Cox 
HR (95% CI) 
Total Population TSH 
 
2271/34,853 0·78 (0·65, 0·95) 0·78 (0·65, 0·95) 0·78 (0·65, 0·95) 907/43,333 0·83 (0·62, 1·09) 0·80 (0·58, 1·12) 0·80 (0·58, 1·12) 
Gender‡ Men 1091/16723 0·80 (0·62, 1·07) 0·80 (0·62, 1·07) 0·80 (0·62, 1·07) 422/21874 0·85 (0·50, 1·41) 0·85 (0·50, 1·41) 0·85 (0·53, 1·38) 
 Women 1180/18130 0·78 (0·58, 1·07) 0·78 (0·58, 1·07) 0·78 (0·62, 1·00) 485/21459 0·80 (0·52, 1·25) 0·80 (0·52, 1·25) 0·80 (0·52, 1·25) 
 
         
Age I§ 18 – 49y 60/8305 0·95 (0·31, 2·86) 0·95 (0·31, 2·86) 0·95 (0·31, 2·86) 12/9,525 0·71 (0·07, 7·47) 0·71 (0·07, 7·47) 0·78 (0·08, 7·78) 
 
50 – 64y 358/9145 0·75 (0·47, 1·19) 0·75 (0·47, 1·19) 0·75 (0·47, 1·19) 104/12,303 1·35 (0·55, 3·25) 1·35 (0·55, 3·25) 1·27 (0·53, 3·03) 
 
65 -79y 1588/15,667 0·83 (0·67, 1·05) 0·83 (0·67, 1·05) 0·83 (0·67, 1·05) 623/19,198 0·89 (0·62, 1·27) 0·87 (0·58, 1·30) 0·87 (0·58, 1·30) 
 
≥80 265/1736 0·69 (0·40, 1·17) 0·69 (0·40, 1·17) 0·65 (0·38, 1·12) 168/2,307 0·43 (0·22, 0·85) 0·43 (0·22, 0·85) 0·43 (0·22, 0·83) 
Abbreviations: CI, confidence interval; DL DerSimonian and Laird; HR, hazard ratio; REML restricted maximum-likelihood ; The HR’s are across the reference range of 
TSH (0·45-4·49 mIU/L) 
*Data were available from 12 studies, 393 participants were excluded due to missing stroke event data. 
† 265 participants were excluded due to missing data on cause of death. 
‡ These analyses were adjusted for age. 
§ These analyses were adjusted for sex and age as continuous variable to avoid residual confounding within age strata. 
 
 
  
Appendix Table 4. Stratified Analyses for the Associations between FT4 in ng/dL and the Risk of All Stroke and Fatal Stroke 
  
All Stroke* Fatal Stroke† 
  
No. events/ Total 
participants 
Age and sex adjusted 
HR (95% CI) 
Multivariable‡ 
HR (95% CI) 
No. events/ Total 
participants 
Age and sex adjusted 
HR (95% CI) 
Multivariable‡ 
HR (95% CI) 
Total Population FT4 
 
1148/22,854 1·40 (0·92, 2·13) 1·32 (0·98, 1·76) 517/30,281 1·42 (1·08, 1·87) 1·31 (1·00, 1·75) 
Gender§ Men 565/10,897 1·10 (0·77, 1·57) 1·27 (0·82, 1·97) 248/15,557 1·37 (0·88, 2·13) 1·20 (0·77, 1·86) 
 Women 583/11,957 1·56 (0·94, 2·59) 1·26 (0·91, 1·74) 269/14,724 1·53 (1·05, 2·23) 1·55 (0·98, 2·43) 
 
p for interaction  0·27 0·98  0·71 0·43 
Age II 18 – 49y 38/7022 0·45 (0·11, 1·93) 0·63 (0·11, 3·47) 7/8190 1·19 (0·09, 15·22) 2·16 (0·08, 16·01) 
 
50 – 64y 284/8496 1·29 (0·40, 4·21) 1·07 (0·48, 2·41) 78/11,310 1·50 (0·68, 3·28) 1·18 (0·52, 2·70) 
 
65 -79y 695/6588 1·54 (1·18, 2·01) 1·50 (1·15, 1·96) 333/9578  1·30 (0·89, 1·90) 1·06 (0·92, 1·22) 
 
≥80 131/748 2·13 (1·03, 4·44) 1·85 (0·58, 5·86) 99/1203  1·79 (0·87, 3·70) 1·39 (0·65, 2·99) 
 
p for trend  0·053 0·18  0·79 0·78 
Abbreviations: CI, confidence interval; HR, hazard ratio; FT4, free thyroxine ( in ng/dL). 
*Data were available from 11 studies, 119 participants were excluded due to missing stroke event data. 
† 27 participants were excluded due to missing data on cause of death.  
‡ Adjusted for sex, age, systolic blood pressure, cholesterol, smoking and prevalent diabetes at baseline.  
§These analyses were not adjusted for sex. 
II These HRs were adjusted for sex and age as continuous variable to avoid residual confounding within age strata. 
 
